Free shipping on all orders over $ 500

ALK5 Inhibitor II

Cat. No. M1859
ALK5 Inhibitor II Structure

SJN 2511

Size Price Availability Quantity
10mg USD 120 In stock
25mg USD 220 In stock
50mg USD 380 In stock
Bulk Inquiry?

Quality Control
Biological Activity

ALK5 Inhibitor is a potent and selective inhibitor of the TGF-β RI kinase with IC50 values of 0.004 and 0.023 μM for ALK5 autophosphorylation and ALK5 binding, respectively. It enhances the efficiency of cellular reprogramming. ALK5 Inhibitor affects a range of related kinases selectively, including p38 MAPK, GSK3 and JNK1 (IC50 > 16 μM).

Cell Experiment
Cell lines iPS cells
Preparation method Cell Cyle Analysis Cells were treated with 25 μΜ RepSox in mES media without feeders for 72 hours and subjected to cell cycle analysis by propidium iodide staining and flow cytometry. Cells were harvested with .25% trypsin and fixed with 70% ethanol overnight. Following at least one hour of incubation with propidium iodide staining solution (50 μg/ml propidium iodide in PBS, .1% BSA, .1% Rnase A) in the dark, samples were analyzed on a BD LRSII Flow Cytometer (BD Biosciences).
Concentrations 25µM
Incubation time 72 h
Animal Experiment
Animal models chimeric embryos E13.5
Formulation not refered
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 287.32
Formula C17H13N5
CAS Number 446859-33-2
Purity >99%
Solubility DMSO ≥5 mg/mL
Storage at -20°C
Related ALK Products
Entrectinib (RXDX-101)

Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.

Crizotinib hydrochloride

Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is useful in treatment of anaplastic large-cell lymphoma.


Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.


ALK-IN-1 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.


CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).

Abmole Inhibitor Catalog 2017

Keywords: ALK5 Inhibitor II, SJN 2511 supplier, ALK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.